In conclusion, TP53MUT AML‐MRC patients had inferior outcomes compared to TP53WT patients irrespective of MRC‐defining criteria, TP53 allelic state, or TP53 VAF. This evidence concerns the gene TP53 and acute myeloid leukemia.